Yuichiro Shirai

744 total citations
28 papers, 418 citations indexed

About

Yuichiro Shirai is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Yuichiro Shirai has authored 28 papers receiving a total of 418 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pathology and Forensic Medicine, 14 papers in Pulmonary and Respiratory Medicine and 7 papers in Epidemiology. Recurrent topics in Yuichiro Shirai's work include Systemic Sclerosis and Related Diseases (17 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (9 papers) and Pulmonary Hypertension Research and Treatments (8 papers). Yuichiro Shirai is often cited by papers focused on Systemic Sclerosis and Related Diseases (17 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (9 papers) and Pulmonary Hypertension Research and Treatments (8 papers). Yuichiro Shirai collaborates with scholars based in Japan, United States and France. Yuichiro Shirai's co-authors include Masataka Kuwana, Tsutomu Takeuchi, Hidekata Yasuoka, Yuichi Tamura, Yuka Okazaki, Mitsuhiro Takeno, Koichi Amano, Tsuneo Kondo, Tatsuya Ito and Hayato Nagasawa and has published in prestigious journals such as PLoS ONE, European Respiratory Journal and Lara D. Veeken.

In The Last Decade

Yuichiro Shirai

26 papers receiving 414 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuichiro Shirai Japan 11 229 176 106 98 60 28 418
Santhanam Lakshminarayanan United States 6 126 0.6× 209 1.2× 142 1.3× 119 1.2× 63 1.1× 17 384
Ashley Pinckney United States 11 240 1.0× 286 1.6× 58 0.5× 105 1.1× 114 1.9× 17 564
Liane te Boome Netherlands 7 147 0.6× 296 1.7× 58 0.5× 71 0.7× 128 2.1× 14 470
José M. Ricart Spain 11 76 0.3× 86 0.5× 90 0.8× 47 0.5× 41 0.7× 39 373
M. Khanfir Tunisia 15 151 0.7× 76 0.4× 275 2.6× 58 0.6× 95 1.6× 68 604
Belén Atienza‐Mateo Spain 15 302 1.3× 94 0.5× 271 2.6× 75 0.8× 118 2.0× 50 552
Kristof Thevissen Belgium 10 89 0.4× 207 1.2× 172 1.6× 70 0.7× 114 1.9× 19 429
Sébastien Sanges France 11 122 0.5× 158 0.9× 64 0.6× 85 0.9× 73 1.2× 44 314
Annet van Royen Netherlands 9 229 1.0× 157 0.9× 144 1.4× 37 0.4× 173 2.9× 13 564
A. Janvresse France 9 247 1.1× 63 0.4× 178 1.7× 254 2.6× 36 0.6× 20 532

Countries citing papers authored by Yuichiro Shirai

Since Specialization
Citations

This map shows the geographic impact of Yuichiro Shirai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuichiro Shirai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuichiro Shirai more than expected).

Fields of papers citing papers by Yuichiro Shirai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuichiro Shirai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuichiro Shirai. The network helps show where Yuichiro Shirai may publish in the future.

Co-authorship network of co-authors of Yuichiro Shirai

This figure shows the co-authorship network connecting the top 25 collaborators of Yuichiro Shirai. A scholar is included among the top collaborators of Yuichiro Shirai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuichiro Shirai. Yuichiro Shirai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ota, Yuko, et al.. (2026). Rapidly progressive fibrinopurulent pleural empyema with systemic juvenile idiopathic arthritis during treatment with tocilizumab. Rheumatology Advances in Practice. 10(1). rkag001–rkag001.
2.
Tamura, Yuichi, Kazuya Hosokawa, Satoshi Ikeda, et al.. (2024). Development and Validation of Quality Indicators for Pulmonary Arterial Hypertension Management in Japan: A Modified Delphi Consensus Study. Diagnostics. 14(23). 2656–2656. 1 indexed citations
3.
Kuwana, Masataka, Kohtaro Abe, Hideyuki Kinoshita, et al.. (2023). Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension. Pulmonary Circulation. 13(1). e12198–e12198. 7 indexed citations
4.
Shirai, Yuichiro, et al.. (2022). Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan. Lara D. Veeken. 61(11). 4491–4496. 8 indexed citations
5.
6.
Avouac, Jérôme, Anne Cauvet, Yuichiro Shirai, et al.. (2020). Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease. PLoS ONE. 15(5). e0232978–e0232978. 38 indexed citations
7.
8.
9.
Gono, Takahisa, et al.. (2019). Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review. Current Rheumatology Reports. 21(4). 10–10. 38 indexed citations
10.
Yasuoka, Hidekata, Yuichiro Shirai, Yuichi Tamura, Tsutomu Takeuchi, & Masataka Kuwana. (2017). Predictors of Favorable Responses to Immunosuppressive Treatment in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease. Circulation Journal. 82(2). 546–554. 32 indexed citations
11.
Kuwana, Masataka, Yuichiro Shirai, & Tsutomu Takeuchi. (2016). Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease. The Journal of Rheumatology. 43(10). 1825–1831. 72 indexed citations
12.
Atanelishvili, Ilia, Yuichiro Shirai, Tanjina Akter, et al.. (2016). D1398G Variant of MET Is Associated with Impaired Signaling of Hepatocyte Growth Factor in Alveolar Epithelial Cells and Lung Fibroblasts. PLoS ONE. 11(9). e0162357–e0162357. 2 indexed citations
13.
Atanelishvili, Ilia, Yuichiro Shirai, Tanjina Akter, et al.. (2015). M10, a caspase cleavage product of the hepatocyte growth factor receptor, interacts with Smad2 and demonstrates antifibrotic properties in vitro and in vivo. Translational research. 170. 99–111. 8 indexed citations
14.
Shirai, Yuichiro, Yuka Okazaki, Yuichi Tamura, et al.. (2014). Elevated Levels of Pentraxin 3 in Systemic Sclerosis: Associations With Vascular Manifestations and Defective Vasculogenesis. Arthritis & Rheumatology. 67(2). 498–507. 48 indexed citations
15.
Shirai, Yuichiro, et al.. (2014). IgG4-related disease in pulmonary arterial hypertension on long-term epoprostenol treatment. European Respiratory Journal. 43(5). 1516–1519. 10 indexed citations
16.
Shirai, Yuichiro, Hidekata Yasuoka, Tsutomu Takeuchi, Toru Satoh, & Masataka Kuwana. (2013). Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center. Modern Rheumatology. 23(6). 1211–20. 12 indexed citations
17.
Kameda, Hideto, Hiroe Ogawa, Hayato Nagasawa, et al.. (2013). Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis. Modern Rheumatology. 23(1). 97–103. 8 indexed citations
18.
Sakai, Ryota, Hayato Nagasawa, Ayumi Okuyama, et al.. (2012). Successful treatment of adult-onset Still’s disease with tocilizumab monotherapy: two case reports and literature review. Clinical Rheumatology. 31(3). 569–574. 33 indexed citations
19.
Kameda, Hideto, Hiroe Ogawa, Hayato Nagasawa, et al.. (2012). Efficacy of weekly mizoribine pulse therapy in refractory lupus nephritis. Modern Rheumatology. 23(1). 97–103. 10 indexed citations
20.
Imura, Yoshitaka, Yuichiro Shirai, Takaki Nojima, et al.. (2012). NEFA/nucleobindin-2 is a target autoantigen of the anti-Wa antibody and is associated with transfer RNA. Modern Rheumatology. 22(5). 685–694. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Santhanam Lakshminarayanan Breakdown of academic impact, for papers by Ashley Pinckney Breakdown of academic impact, for papers by Liane te Boome Breakdown of academic impact, for papers by José M. Ricart Breakdown of academic impact, for papers by M. Khanfir Breakdown of academic impact, for papers by Belén Atienza‐Mateo Breakdown of academic impact, for papers by Kristof Thevissen Breakdown of academic impact, for papers by Sébastien Sanges Breakdown of academic impact, for papers by Annet van Royen Breakdown of academic impact, for papers by A. Janvresse
Rankless by CCL
2026